MARLBOROUGH, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced a collaboration with the Singapore Translational Cancer Consortium (STCC) on the STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study. This initiative aims to identify and validate key biomarkers predicting response or refractoriness to immune checkpoint inhibitors using Akoya's IO60 panel for spatial proteomic analysis. Advancing Precision Immunotherapy ...